Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trastuzumab: updates and future issues.

Masakazu Toi1, Kazumi Horiguchi, Hiroko Bando

  • 1Department of Clinical Trial and Research, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Honkomagome 3-18-22, Bunkyo-ku, Tokyo, 113-8677, Japan. maktoi77@wa2.so-net.ne.jp

Cancer Chemotherapy and Pharmacology
|November 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting Anthracycline-Induced Cardiotoxicity Using the HFA-ICOS Risk Score: A Validation Study From AIC Registry.

JACC. Asia·2026
Same author

Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer.

Breast cancer research : BCR·2026
Same author

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.

Ecancermedicalscience·2026
Same author

Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Breast cancer research and treatment·2026
Same author

Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial.

Breast cancer (Tokyo, Japan)·2026
Same author

Reactive oxygen species generation by photothermal effects of adhesive near-infrared agents on the plasma membrane.

Journal of clinical biochemistry and nutrition·2026

Trastuzumab significantly improves survival for HER2-positive metastatic breast cancer patients. Further research is needed to optimize individualized trastuzumab therapies by understanding response mechanisms and Her-axis/hormone-axis interactions.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Trastuzumab has revolutionized HER2-positive breast cancer treatment, improving patient survival.
  • Its efficacy in neoadjuvant settings with chemotherapy is well-established, leading to high pathological complete response rates.

Purpose of the Study:

  • To provide a precise understanding of trastuzumab's therapeutic response mechanisms.
  • To explore the intricate interactions between the HER2-axis and hormone-axis.
  • To guide the optimization of individualized trastuzumab-based therapies.

Main Methods:

  • Review of existing clinical and preclinical studies on trastuzumab.
  • Analysis of data regarding HER2-axis and hormone-axis crosstalk.
  • Discussion of mechanisms underlying therapeutic response and resistance.

Related Experiment Videos

Main Results:

  • Trastuzumab therapy has demonstrably improved survival outcomes in HER2-positive metastatic breast cancer.
  • High pathological complete response rates are observed with trastuzumab-based neoadjuvant chemotherapy.
  • The interplay between HER2 and hormone signaling pathways warrants deeper investigation for treatment optimization.

Conclusions:

  • A comprehensive understanding of trastuzumab's mechanisms is crucial for personalized treatment strategies.
  • Investigating the HER2-axis and hormone-axis interaction may unlock new therapeutic avenues.
  • Individualized optimization of trastuzumab-based therapies holds significant promise for breast cancer management.